We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celanese (CE) to Promote VitalDose EVA at CRS Annual Meet
Read MoreHide Full Article
Celanese Corporation (CE - Free Report) will feature VitalDose ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants at the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition, from Jul 17–20 in Seattle, WA.
Celanese VitalDose EVA, a controlled release material, is meeting the increasing needs of the industry as pharmaceutical companies are searching for better administrative methods to boost efficacy and improve patient drug compliance. It helps manufacturers derive a polymer as per their needs, which would provide them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.
VitalDose EVA allows manufacturers to customize the release rate of drugs used in implantable drug delivery devices. This copolymer, which blends soundly with other polymers, can be used alone as well as with other excipients or additives to attain the required release rate. VitalDose EVA is used by pharmaceutical companies in a large range of drug delivery applications such as transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal.
Celanese’s shares rose 2.8% to close at $67.14 on Jul 8.
Celanese’s adjusted earnings for first-quarter 2016 were $1.83 per share, indicating a 6% increase from the prior-year quarter. Earnings per share also beat the Zacks Consensus Estimate of $1.52. Although revenues dropped roughly 3% year over year to $1,404 million in the quarter, the figure beat the Zacks Consensus Estimate.
Celanese also upgraded its outlook for 2016. It now expects an improvement of 8%−10% in earnings per share, compared to 5%−10% growth stated earlier. The company intends to pursue commercial discipline coupled with excellence in operation and productivity, to survive and grow in the current environment.
Celanese currently carries a Zacks Rank #3 (Hold).
Better-ranked companies in the chemicals industry include Axiall Corporation , Albemarle Corporation (ALB - Free Report) and Asahi Kasei Corp. (AHKSY - Free Report) , all sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Celanese (CE) to Promote VitalDose EVA at CRS Annual Meet
Celanese Corporation (CE - Free Report) will feature VitalDose ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants at the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition, from Jul 17–20 in Seattle, WA.
Celanese VitalDose EVA, a controlled release material, is meeting the increasing needs of the industry as pharmaceutical companies are searching for better administrative methods to boost efficacy and improve patient drug compliance. It helps manufacturers derive a polymer as per their needs, which would provide them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.
VitalDose EVA allows manufacturers to customize the release rate of drugs used in implantable drug delivery devices. This copolymer, which blends soundly with other polymers, can be used alone as well as with other excipients or additives to attain the required release rate. VitalDose EVA is used by pharmaceutical companies in a large range of drug delivery applications such as transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal.
Celanese’s shares rose 2.8% to close at $67.14 on Jul 8.
CELANESE CP-A Price
CELANESE CP-A Price | CELANESE CP-A Quote
Celanese’s adjusted earnings for first-quarter 2016 were $1.83 per share, indicating a 6% increase from the prior-year quarter. Earnings per share also beat the Zacks Consensus Estimate of $1.52. Although revenues dropped roughly 3% year over year to $1,404 million in the quarter, the figure beat the Zacks Consensus Estimate.
Celanese also upgraded its outlook for 2016. It now expects an improvement of 8%−10% in earnings per share, compared to 5%−10% growth stated earlier. The company intends to pursue commercial discipline coupled with excellence in operation and productivity, to survive and grow in the current environment.
Celanese currently carries a Zacks Rank #3 (Hold).
Better-ranked companies in the chemicals industry include Axiall Corporation , Albemarle Corporation (ALB - Free Report) and Asahi Kasei Corp. (AHKSY - Free Report) , all sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>